Edition:
United States

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

194.01USD
22 Jul 2019
Change (% chg)

$-0.32 (-0.16%)
Prev Close
$194.33
Open
$195.22
Day's High
$196.75
Day's Low
$193.70
Volume
275,785
Avg. Vol
362,130
52-wk High
$197.30
52-wk Low
$134.53

Summary

Name Age Since Current Position

Michael Mussallem

66 2000 Chairman of the Board, Chief Executive Officer

Scott Ullem

52 2014 Chief Financial Officer, Corporate Vice President

Jean-Luc Lemercier

61 2017 Corporate Vice President - EMEA (Europe, Middle East and Africa)

Donald Bobo

57 2015 Corporate Vice President - Strategy and Corporate Development

Catherine Szyman

52 2015 Corporate Vice President - Critical Care

Huimin Wang

62 2010 Corporate Vice President - Japan, Asia and Pacific

Larry Wood

53 2018 Corporate Vice President - Transcatheter Aortic Valve Replacement

Wesley von Schack

74 2018 Lead Independent Director

Kieran Gallahue

55 2015 Independent Director

Leslie Heisz

58 2016 Independent Director

William Link

72 2009 Independent Director

Steven Loranger

67 2016 Independent Director

Martha Marsh

70 2015 Independent Director

Nicholas Valeriani

62 2014 Independent Director

Biographies

Name Description

Michael Mussallem

Mr. Michael A. Mussallem is Chairman of the Board, Chief Executive Officer of the Edwards Lifesciences Corp. He has an extensive knowledge of the medical technology industry in general, and of the people, operations, processes and products of the Company in particular, built over a more than 35-year career with the Company and its predecessor. In addition, in his roles with AdvaMed and other healthcare-related organizations, he has become a recognized leader in the medical technology industry, making important contributions to healthcare policy discussions in California, the United States and the key global markets that the Company serves. These experiences have established relationships, which are helpful in developing our Board’s strategic perspective, and enhanced his leadership of the Company and contributions to our Board.

Scott Ullem

Mr. Scott B. Ullem is Chief Financial Officer, Corporate Vice President of the Edwards Lifesciences Corportion. Mr. Ullem became Corporate Vice President, Chief Financial Officer in January 2014. Prior to joining Edwards, he served from May 2010 to December 2013 as Chief Financial Officer of Bemis Company Inc., a Fortune 500 publicly traded global supplier of packaging and pressure sensitive materials used in leading food, consumer, and healthcare products. Mr. Ullem also had leadership responsibility for one of Bemis’ three business segments and the company’s information technology function. Before joining Bemis, Mr. Ullem spent 17 years in investment banking, serving as Managing Director at Goldman Sachs and later at Bank of America. He has served on the Board and Compensation Committee of Berry Global Inc. since 2016 and is a Henry Crown Fellow at the Aspen Institute.

Jean-Luc Lemercier

Mr. Jean-Luc Lemercier has been Corporate Vice President - EMEA (Europe, Middle East and Africa) of the Edwards Lifesciences Corp, Canada and Latin America since July 2017. Prior to assuming his current role, Mr. Lemercier served as Vice President of Transcatheter Heart Valves EMEA from 2008 to 2017. Under his leadership, Edwards successfully launched the SAPIEN transcatheter heart valve technology and built its leadership position in Europe. Before joining Edwards, Mr. Lemercier served in various leadership roles with Johnson & Johnson Cordis from 1996 to 2008, including leader of the structural heart disease group in the United States; Vice President of New Business Development in Europe; Vice President of the Cordis Cardiology Division in Belgium; and General Manager of Cordis France. Mr. Lemercier has more than 30 years of medical technology experience, beginning with Baxter in France, and held several sales and marketing management positions within Baxter Europe and the United States. Mr. Lemercier has served on the Board of CARMAT since January 2017.

Donald Bobo

Mr. Donald E. Bobo Jr. is Corporate Vice President - Strategy and Corporate Development of Edwards Lifesciences Corp. Mr. Bobo has been Corporate Vice President since 2007 and is responsible for Edwards’ corporate strategy and corporate development functions. In addition, Mr. Bobo has executive responsibility for the Company’s disease awareness and heart failure initiatives, as well as the healthcare solutions and commercial services team. Mr. Bobo has more than 30 years of experience in the medical products and healthcare industry and has served in various operating roles at Edwards, including most recently, the leadership of the Company’s transcatheter mitral and tricuspid therapies organization, the global heart valve therapy business and global valve manufacturing operations. Prior to joining Edwards in 1995, Mr. Bobo held a variety of roles with increasing levels of responsibility with American Hospital Supply and Baxter Healthcare Corporation. He has served on the Board and Executive Committee of the California Life Sciences Association since 2015 and served as its Chairman of the Board from May 2017 to May 2018.

Catherine Szyman

Ms. Catherine M. Szyman has been Corporate Vice President - Critical Care of Edwards Lifesciences Corporation since January 2015. Prior to 2015, she was employed for more than 20 years at Medtronic, LLC, where she served as its Senior Vice President and President of Medtronic’s global diabetes business from 2009 to 2014, overseeing research, development, operations, sales and marketing for Medtronic’s insulin infusion pumps and continuous glucose monitoring systems. Prior to that, she held a variety of leadership roles at Medtronic, including Senior Vice President of Corporate Strategy and Business Development, General Manager of Endovascular Innovations and Vice President of Finance for the Cardiovascular Business. Ms. Szyman previously served on the Boards of Tornier, Inspire Medical Systems, and the California Healthcare Institute.

Huimin Wang

Dr. Huimin Wang M.D. is Corporate Vice President - Japan, Asia and Pacific of Edwards Lifesciences Corporation. since 2010. From 2004 to 2010, he served as Corporate Vice President, Japan and Intercontinental Regions and was Corporate Vice President, Japan from 2000 to 2004. Previously, he served in a number of roles with Baxter Healthcare Corporation, including Senior Manager of Strategy Development, Director of Product/Therapy for the Renal Division in Japan, President of Medical Systems and Devices in Japan, and was a representative director of Baxter Limited, a Japan corporation, through September 2002. Before joining Baxter, Dr. Wang was a senior associate with Booz, Allen & Hamilton in Chicago, Vice President of Integrated Strategies, a consulting and venture management firm he co-founded, and an associate with McKinsey & Company.

Larry Wood

Mr. Larry L. Wood is Corporate Vice President - Transcatheter Aortic Valve Replacement of Edwards Lifesciences Corp. Mr. Wood has been Corporate Vice President, Transcatheter Aortic Valve Replacement since 2007. He is responsible for Edwards’ key initiatives in transcatheter heart valve replacement around the globe, including research and development, operations, marketing, commercial clinical and regulatory initiatives. Most recently prior to his current role, from March 2004 to February 2007, he served as Vice President and General Manager, Percutaneous Valve Interventions. Mr. Wood has more than 30 years of experience in the medical technology industry at both Edwards and Baxter Healthcare Corporation in positions including manufacturing management, regulatory affairs and strategic and clinical marketing, primarily for the surgical heart valve therapy business.

Wesley von Schack

Dr. Wesley W. von Schack is Lead Independent Director of the Edwards Lifesciences Corp. Mr. von Schack’s experience of more than 30 years in the highly regulated energy industry as both a chief executive officer and a chief financial officer, combined with many years of board experience and audit and compensation committee chairmanships, enable him to make significant contributions in assessing and managing risks. In addition, the operational and leadership skills developed over his career have provided valuable insights and support to our Board as its Lead Independent Director.

Kieran Gallahue

Mr. Kieran T. Gallahue is an Independent Director of the Edwards Lifesciences Corporation. Mr. Gallahue provides valuable insights and direction to our Board gained through extensive executive management experience at medical technology companies. His leadership roles on other public company boards and committees and prior experience as a public company chief financial officer also enables him to contribute valuable financial and accounting perspectives to our Board and Audit Committee.

Leslie Heisz

Ms. Leslie Stone Heisz is an Independent Director of the Edwards Lifesciences Corp. Ms. Heisz’s career in the banking industry, in-depth knowledge of capital markets, and previous public company board and audit committee experience enhances our Board’s ability to effectively oversee financial reporting, enterprise and operational risk management, as well as corporate finance, tax, treasury, and governance matters.

William Link

Dr. William J. Link Ph.D. is an Independent Director of the Edwards Lifesciences Corp. Dr. Link’s corporate leadership and long history successfully commercializing products in the medical technology industry provide our Board with a valuable perspective in evaluating the prospects of, and risks associated with, existing business operations. In addition, his extensive experience in identifying new business opportunities and his strong technical and engineering background have proven beneficial in assessing the potential for future innovations.

Steven Loranger

Mr. Steven R. Loranger is an Independent Director of the Edwards Lifesciences Corp. Mr. Loranger is a seasoned executive with global manufacturing and operational experience in highly regulated, high-tech industries. His decades of experience leading large, global innovation-focused corporations with intensive data privacy components is particularly valuable to our Board.

Martha Marsh

Ms. Martha H. Marsh is Independent Director of the Edwards Lifesciences Corp. Ms. Marsh’s experience of more than 30 years in an increasingly complex and evolving healthcare system as a president and chief executive officer, combined with years of board experience that includes corporate governance chairmanships, provide a unique perspective as our Board considers the execution of our patient-focused innovation strategy.

Nicholas Valeriani

Mr. Nicholas J. Valeriani is an Independent Director of the Edwards Lifesciences Corp. Mr. Valeriani’s 40 years of medical technology industry experience in a large and complex global company and experience directing strategy informs his contribution to the development of our innovation strategy and assessment of future business opportunities. In addition, his background in human resources enables him to contribute valuable insights to the Compensation and Governance Committee.

Basic Compensation

Name Fiscal Year Total

Michael Mussallem

10,278,900

Scott Ullem

3,021,830

Jean-Luc Lemercier

--

Donald Bobo

2,903,400

Catherine Szyman

2,794,690

Huimin Wang

--

Larry Wood

2,918,400

Wesley von Schack

320,117

Kieran Gallahue

295,117

Leslie Heisz

306,291

William Link

308,117

Steven Loranger

281,291

Martha Marsh

289,997

Nicholas Valeriani

289,997
As Of  30 Dec 2018

Options Compensation